OptiBiotix Health PLC Anthem BioPharma launches two products in India
17 Diciembre 2019 - 01:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
17 December 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Anthem BioPharma launches two products formulated with
SlimBiome(R) to the Indian market
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skincare, announces the commercial launch of two products
formulated with SlimBiome(R) to the Indian market in partnership
with Anthem BioPharma and Zeon Life Sciences.
Anthem BioPharma (www.anthembiopharma.com), an Anthem
Biosciences Pvt Ltd company, is a fully integrated Indian
Pharmaceutical and Biotechnology company with a turnover of GBP90
million in FY 2019-20 and launched two products formulated with
SlimBiome(R) to the Indian market on 16 December 2019. The products
are 1) Metalite - a supplement to aid with effective weight
management and 2) Metalite Pro - a high protein meal replacement
(www.metalitepro.com).
Pratik Girish Ligade, Marketing & Sales Business Head -
Diabetology, commented: "India is currently one of the most
attractive potential markets for the health and wellness industry
due to its large, fast urbanizing population. Increasing stress and
unhealthy lifestyle, has made nearly 1 out of 4 adults overweight.
The main reasons behind this alarming situation is an increase in
the consumption of processed food, lower levels of physical
activity and increased professional and personal life pressures.
Truncal obesity in adults and teens, unhealthy food choices and
contamination of food, water and air in cities is creating a
perfect storm of lifestyle diseases. Consumers are becoming aware
of the serious health risks resulting from their new lifestyle
choices and are willing to do something about it. As a result,
there is an increase in wellness products and dietary supplements
product offerings targeting weight loss, however, there is hardly
any clinically tested meal replacement product available in India.
It gives Anthem a great opportunity to make an impact in this
space, and we believe SlimBiome(R) will play an important role in
addressing the obesity pandemic that continues to increase. We
chose SlimBiome(R) because it is scientifically formulated and
clinically proven to function in weight management
applications."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division, commented: "We are very pleased to announce this
commercial launch in partnership with Anthem BioPharma and Zeon
Life Sciences, the exclusive manufacturer of SlimBiome(R) in India.
This launch is the start of recurrent revenues in India and we are
confident in our capacity to replicate similar deals in other
markets in the near future now that we have production partners in
North America, the UK, Europe and India."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate
Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy optibiotix@walbrookpr.com
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALLFLDFDLRLIA
(END) Dow Jones Newswires
December 17, 2019 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024